Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

Objectives: On the basis of the positive results of CheckMate-743, first-line (1L) treatment of malignant pleural mesothelioma (MPM) with the combination of ipilimumab and nivolumab (ipi-nivo) has become a standard-of-care. Furthermore, patients who received 1L platinum/pemetrexed chemotherapy are o...

Повний опис

Бібліографічні деталі

Автори:	Sabine Schmid, MD, Lisa Holer, MSc, Katrin Gysel, MSc, Kira-Lee Koster, MD, Sacha I. Rothschild, MD, Laura A. Boos, MD, Lorenz Frehner, MD, Sabine Cardoso Almeida, MD, Christian Britschgi, MD, PhD, Yannis Metaxas, MD, Michael Mark, MD, Patrizia Froesch, MD, Wolf-Dieter Janthur, MD, Anna Allemann, MD, Christine Waibel, MD, Catherine Von der Mühll-Schill, MD, Martin Früh, MD, Laetitia A. Mauti, MD, PhD
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Elsevier 2024-12-01
Серія:	JTO Clinical and Research Reports
Предмети:	Malignant pleural mesothelioma Ipilimumab Nivolumab Real-world Outcome
Онлайн доступ:	http://www.sciencedirect.com/science/article/pii/S266636432400105X
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!